246P - The association of plasma soluble major histocompatibility complex class I polypeptide-related sequence A (sMICA) level with the pathological compl...

Date 17 December 2016
Event ESMO Asia 2016 Congress
Session Poster lunch
Topics Oesophageal Cancer
Pathology/Molecular Biology
Translational Research
Presenter Hung-Yang Kuo
Citation Annals of Oncology (2016) 27 (suppl_9): ix68-ix85. 10.1093/annonc/mdw582
Authors H. Kuo1, Y. Lin2, J. Guo3, T. Huang3, C. Lin3, K. Yeh3, A. Cheng3, C. Hsu3, C. Chang2
  • 1Oncology Division/department Of Internal Medicine, National Taiwan University Hospital Hsin-Chu Branch, 300 - Hsinchu City/TW
  • 2Institute Of Molecular And Cellular Biology And Department Of Life Science, National Tsing Hua University, 30013 - Hsinchu City/TW
  • 3Oncology Department, National Taiwan University Hospital, 10048 - Taipei/TW



MICA is a ligand for the NKG2D receptors expressed on NK cells and certain types of T cells. Under various types of stress, MICA is induced and shed from the cell surface into the circulation generating a soluble form (sMICA). The sMICA level has been reported to be associated with disease progression of several malignancies and its significance in ESCC patients is unknown.


Thirty-one patients with locally advanced ESCC (all AJCC 6th ed. T3N0-1M0-1a) who had undergone neoadjuvant paclitaxel/cisplatin-based chemoradiotherapy (CRT) followed by esophagectomy in a prospective phase II clinical trial (Lin CC et al: J Clin Oncol 2013;31; suppl; abstr 4099) were included. Their plasma sMICA levels were measured by quantitative ELISA before CRT, after CRT, and after surgery, and then correlated with pCR rate and survival outcomes.


With a median follow-up of 51.0 months, the median recurrence-free survival (RFS) and overall survival (OS) of these patients was 23.7(95%C.I. 25.1-48.1) and 51.0 (95%C.I. 39.9-61.1) months. The median (range) of baseline, post-CRT and post-surgery sMICA level was 66.5 (26.1-457.5), 65.0 (25.2-534.6) and 66.9 (25.4-377.3) pg/ml. Patients with low baseline sMICA, defined as less than the median level, had significantly higher pCR rate than those with high baseline sMICA [62.5% (10/16) vs. 20% (3/15), p = 0.017]. The median RFS (33.9 vs. 22.9m, p = 0.811) and OS (51.0 vs. 51.0m, p = 0.827) were not significantly different between patients with low and high baseline sMICA levels.rn

Table: 246P

Baseline plasma sMICA level and pCR rate (n = 31)
Baseline plasma sMICApCR rateMedian RFS(m)Median OS(m)
All41.9% (13/31)23.751.0
High20.0% (3/15)22.951.0
Low62.5% (10/16)33.951.0


In this relatively small cohort, the low plasma sMICA level was associated with an increased pCR rate in locally advanced ESCC treated with neoadjuvant CRT. Further confirmatory studies with a larger patient population are warranted. (The work was supported by the Grant of HCH105-021 and MOST 104-2320-B-007-002)

Clinical trial indentification


Legal entity responsible for the study

National Taiwan University Hospital and Hsin-Chu Branch, National Tsing Hua University


National Taiwan University Hospital Hsin-Chu Branch, Ministry of Science and Technology


All authors have declared no conflicts of interest.